These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20340038)

  • 1. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas.
    Tanji N; Ozawa A; Miura N; Yanagihara Y; Sasaki T; Nishida T; Kikugawa T; Ikeda T; Ochi T; Shimamoto K; Aoki K; Yokoyama M
    Int J Clin Oncol; 2010 Aug; 15(4):369-75. PubMed ID: 20340038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience.
    Ozawa A; Tanji N; Ochi T; Yanagihara Y; Kikugawa T; Yamaguchi A; Ikeda T; Shimamoto K; Aoki K; Toshino A; Yokoyama M
    Int J Clin Oncol; 2007 Aug; 12(4):279-83. PubMed ID: 17701007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.
    Yamamoto K; Sasano T; Tsuji D; Ishizuka Y; Tokou U; Nakamichi H; Yoneda T; Shiokawa M; Yabe K
    Ann Pharmacother; 2019 Jul; 53(7):690-696. PubMed ID: 30734587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.
    Tanji N; Fukumoto T; Miura N; Yanagihara Y; Azuma K; Sasaki T; Nishida T; Kikugawa T; Shimamoto K; Aoki K; Yokoyama M
    Anticancer Res; 2010 Sep; 30(9):3839-43. PubMed ID: 20944180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
    Hahn NM; Stadler WM; Zon RT; Waterhouse D; Picus J; Nattam S; Johnson CS; Perkins SM; Waddell MJ; Sweeney CJ;
    J Clin Oncol; 2011 Apr; 29(12):1525-30. PubMed ID: 21422406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.
    Gondo T; Ohori M; Hamada R; Tanaka A; Satake N; Takeuchi H; Nakashima J; Hatano T; Tachibana M
    Int J Clin Oncol; 2011 Aug; 16(4):345-51. PubMed ID: 21331770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
    Miyata Y; Nomata K; Ohba K; Matsuo T; Sagara Y; Kanetake H; Sakai H
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):451-9. PubMed ID: 22864875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency.
    Tanji N; Fukumoto T; Miura N; Yanagihara Y; Shirato A; Azuma K; Miyauchi Y; Kikugawa T; Shimamoto K; Yokoyama M
    Int J Clin Oncol; 2013 Oct; 18(5):910-5. PubMed ID: 22936563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].
    Sumiyoshi T; Matsumoto K; Utsunomiya N; Segawa T; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2013 Jan; 59(1):1-6. PubMed ID: 23412116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
    Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
    Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
    Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
    Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
    Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.
    Soga N; Kise H; Arima K; Sugimura Y
    Int J Clin Oncol; 2010 Aug; 15(4):376-81. PubMed ID: 20333430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.